CoChat

The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial

Open access
Ahmadi, Jamshid, Jahromi, Mina Sefidfard, Ehsaei, Zahra · 2018 · Trials

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Buprenorphine is usually administered to treat opioid use disorder and pain syndromes. This research presents the first study regarding the effectiveness of different singly administered high doses of buprenorphine (a partial opioid agonist (of μ-opioid receptors), a potent opioid antagonist (of κ-receptors) and a partial agonist of nociception receptors) in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence. It follows small studies that suggest that ultra-low-dose buprenorphine may be useful in reducing suicidal ideation. The goal of this study was to describe the outcome of different doses of buprenorphine on suicidal opioid-dependent patients over a 3-day interval, by conducting a randomized clinical trial. METHODS: Fifty-one suicidal male inpatients who fulfilled the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for both opioid dependence and major depressive disorder were randomized to three groups (n = 17 per group) to receive a single, sublingual dose of buprenorphine (32 mg, 64 mg, or 96 mg). Out of 51 participants, there were 47 patients; 16 (34.04%) received 32 mg, 17 (36.17%) received 64 mg, and 14 (29.78%) received 96 mg of sublingual buprenorphine. They were evaluated by using psychometric assessment of the Beck Scale for Suicidal Ideation (BSSI) and interviews based on DSM-5 criteria. A placebo group was not included because of the high probability of severe withdrawal without active pharmacological treatment. The study was conducted with appropriate precautions and monitoring of respiratory and cardiovascular measures. The medication was administered while the patients were in moderate opiate withdrawal, as indicated by the presence of four to five withdrawal symptoms. A structured clinical interview was conducted, and urine toxicology testing was performed. RESULTS: Patients completed the 3-day trial course. The outcomes illustrated a significant reduction in BSSI scores within each of the three groups, p < 0.01., but no difference in results between the groups, p = 0.408. CONCLUSIONS: The results suggest that a single high dose of buprenorphine could rapidly treat suicidal ideations. A single high dose of buprenorphine may be a main-mechanism medication that gives a rapid treatment for suicidal opioid-dependent patients. Placebo-controlled trials are required to measure the safety and the physiological and psychological effects of this medication.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13063-018-2843-9

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flowchart of the patients in this trial
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flowchart of the patients in this trialCC BY · PubMed Central
Fig. 2 CONSORT 2010 checklist of information to include when reporting a randomized trial
Fig. 2 CONSORT 2010 checklist of information to include when reporting a randomized trialCC BY · PubMed Central
Fig. 3 Beck Scale for Suicidal Ideation (BSSI) results for the three groups during the 3 days following buprenorphine administration (repeated measures)
Fig. 3 Beck Scale for Suicidal Ideation (BSSI) results for the three groups during the 3 days following buprenorphine administration (repeated measures)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 42 references

Research works printed but not linked: 3

  1. Ahmadi J Instant detoxification of heroin with high dose of buprenorphine J Addict Prev 2016 4 1 3
  2. Moggi F Etiological models on the relationship of mental disorders and substance use disorders Suchtmed 2013 15 327 333
  3. Soyka M. Affective and anxiety disorders and drug addiction. Suchtmed, German. 2013;15:341–8.

Cited by

See all 53

Metadata

Authors
Ahmadi, J., Jahromi, M. S., & Ehsaei, Z.
Affiliations
Shiraz University of Medical Sciences (IR)
Corresponding author
Ahmadi, Jamshid
Venue
Trials
Published
2018-08-29
Volume
19
Issue
1
Pages
462-462
ISSN
1745-6215 (ISSN-L)
OpenAlex
W2889521581
Cited by
48
References
43
Citations by year
2026: 6 · 2025: 4 · 2024: 2 · 2023: 4 · 2022: 9 · 2021: 8 · 2020: 9 · 2019: 6
FWCI
5.48
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Trials (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Shiraz University of Medical Sciences (IR.SUMS.REC.1395.102,)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
buprenorphine, suicidal ideation, major depressive disorder, opioid use disorder, comorbidities, high-dose buprenorphine, sublingual administration, opioid withdrawal, dose comparison, suicide prevention, depression treatment, opioid antagonists, mu-opioid receptor agonists, kappa opioid receptor
MeSH terms
Administration, Sublingual, Adult, Analgesics, Opioid, Antidepressive Agents, Buprenorphine, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Humans, Iran, Male, Opioid-Related Disorders, Substance Withdrawal Syndrome, Time Factors, Comorbidity, Treatment Outcome, Suicidal Ideation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. https://app.cochat.ai/papers/10.1186/s13063-018-2843-9
The paper
Ahmadi, J., Jahromi, M. S., & Ehsaei, Z. (2018). The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. Trials. https://doi.org/10.1186/s13063-018-2843-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.